LACTOLOGY FOUNDATION

Lafutidine (ATC A02BA08) is a second‑generation histamine H2‑receptor antagonist with multimodal gastroprotective activity and a generally favorable toxicity and lactation‑safety profile, but with very limited direct data on excretion into human milk, so risk assessment during breastfeeding is largely extrapolated from class data on H2‑blockers and general pharmacokinetic principles.

Drug class and indication

Lafutidine belongs to ATC class A02BA08: H2‑receptor antagonists used in the treatment of peptic ulcer disease and gastro‑oesophageal reflux disease.
Approved indications include treatment of erosive esophagitis, short‑term therapy of active duodenal and benign gastric ulcers, long‑term prevention of duodenal ulcer relapse and gastric hypersecretory states, therapy of gastro‑oesophageal reflux, prophylaxis of upper GI bleeding in critically ill patients, adjunctive treatment in corrosive acid ingestion, and relief of heartburn.

Mechanism of action and pharmacology

Like other H2‑receptor antagonists, lafutidine suppresses gastric acid secretion by competitively blocking histamine H2 receptors on parietal cells.
In addition, it exhibits unique multimodal gastroprotective actions: enhancement of gastric mucosal blood flow via nitric‑oxide–mediated pathways, stimulation of mucin production, inhibition of neutrophil activation in the gastric mucosa, and interference with Helicobacter pylori adhesion to gastric epithelial cells.

Lafutidine has a molecular weight of about 431.5 Da and shows rapid, nearly complete gastrointestinal absorption after oral administration.
Mucoadhesive tablet formulations adhere to the gastric mucosa for approximately 10 hours, providing prolonged local delivery, while the reported plasma elimination half‑life is around 1.9 hours (± 0.8 h).

General toxicity profile

In clinical use, lafutidine is generally well tolerated and considered to have a favorable toxicological profile.
Reported adverse reactions are usually mild and infrequent and include nausea, vomiting, constipation or diarrhea, flushing reactions, rash, dizziness, and occasional increases in liver enzymes or respiratory/psychiatric symptoms in post‑marketing experience.

Serious toxicity is rare at therapeutic doses, and overdose experience is very limited; expected manifestations would be an extension of its pharmacodynamic effects (e.g., gastrointestinal symptoms, potential CNS manifestations in extreme exposures), analogously to other H2‑receptor antagonists.
Standard supportive management, monitoring of vital signs, and symptomatic treatment are generally appropriate in accidental overdose, with consideration of decontamination only in substantial, recent oral exposures.

Reproductive toxicity and pregnancy

In the Lactologia monograph, lafutidine is classified as FDA pregnancy category B based on preclinical data.
Category B traditionally implies that animal reproduction studies have not demonstrated a fetal risk, although controlled studies in pregnant women are lacking, or that adverse findings in animals have not been confirmed in adequate human studies.

Current regulatory practice has moved away from letter categories toward narrative Pregnancy and Lactation Labeling Rule (PLLR) sections, but legacy data can still guide risk assessment for older drugs.
In the absence of human teratogenicity signals and given the class experience with H2‑receptor antagonists (which are widely used in pregnancy without clear evidence of major malformative risk), lafutidine may be considered a relatively low‑risk option when acid‑suppressive treatment is clearly indicated in pregnant patients, although better‑studied alternatives are generally preferred.

Lactation: excretion into milk and infant exposure

The Lactologia source explicitly notes that there are no data on the plasma:milk concentration ratio for lafutidine.
No specific human or animal quantitative studies describing lafutidine levels in breast milk or infant serum were identified in the available literature.

General principles of drug excretion into breast milk indicate that most small molecules with moderate molecular weight (< 800 Da) cross into milk to some degree, but the clinical relevance depends on protein binding, lipid solubility, pKa, and half‑life.
Given lafutidine’s moderate molecular weight, relatively short plasma half‑life, and the very modest infant exposures observed with other H2‑blockers (cimetidine, ranitidine, famotidine, nizatidine), overall infant exposure after maternal therapeutic dosing is expected to be low, though this remains an extrapolation rather than a measured fact.

Lactation: class data for H2‑receptor antagonists

Published data for H2‑receptor antagonists as a class suggest that breastfed infants are exposed to small amounts of these drugs via milk, generally well below therapeutic doses used directly in neonates and infants.
A UK medicines Q&A concludes that, although data for individual agents can be limited, use of H2‑receptor antagonists in breastfeeding mothers does not appear to pose a significant risk to infants; ranitidine is usually considered first‑line due to greater experience, and treatment should be with the lowest effective dose and shortest duration.

Cimetidine and ranitidine are known to accumulate to some extent in breast milk, with a milk:plasma ratio above 1, but even then the absolute infant dose is low and rarely clinically significant.
No adverse effects have been consistently reported in breastfed infants exposed to therapeutic maternal doses of H2‑blockers, though routine clinical surveillance of growth, feeding, and unusual symptoms is advised.

Lactation risk categorization for lafutidine

Based on the Lactologia classification, lafutidine is placed in toxico‑lactational category II, which corresponds to low expected risk in breastfeeding, with some theoretical or minor concerns and the recommendation for medical supervision.
The absence of specific milk‑level data, combined with favorable pharmacokinetics (short half‑life, no accumulation described, local gastric delivery from mucoadhesive tablets) and an overall benign toxicity profile, supports this intermediate‑safety categorization rather than a “very safe / category I” designation.

Clinically, if a breastfeeding mother requires an H2‑receptor antagonist, better‑studied options such as ranitidine or famotidine are typically preferred where available, but substitution may not always be feasible due to local regulatory or market factors.
When lafutidine is used during lactation, it can be considered compatible under medical supervision in healthy term infants, with attention to dose optimization and infant monitoring, consistent with class recommendations.

Practical lactation recommendations

When prescribing lafutidine to a breastfeeding woman, clinicians should first re‑evaluate the need for pharmacologic acid suppression and consider non‑pharmacological measures where appropriate.
If treatment is necessary and lafutidine is selected, the lowest effective dose and shortest effective course should be used, avoiding high‑dose or prolonged therapy whenever possible.

No specific waiting time between dosing and breastfeeding can be recommended due to the lack of milk pharmacokinetic data, but administering the dose immediately after a feed and allowing a longer interval before the next feed may theoretically reduce peak infant exposure for short‑acting drugs.
Breastfed infants should be monitored for feeding difficulties, unusual drowsiness or irritability, gastrointestinal disturbances (diarrhea, constipation), or rash; if such symptoms appear temporally related to maternal therapy, clinical reassessment is advisable.

Special situations and high‑risk infants

Caution is warranted in premature infants, newborns with significant comorbidities (cardiorespiratory, renal, hepatic disease), or those receiving concurrent medications with potential interactions or overlapping toxicity.
In such high‑risk groups, the benefit–risk ratio should be carefully individualized, and consideration given to either alternative maternal therapy with better lactation data or temporary partial interruption of breastfeeding in extreme cases, although this is rarely necessary with H2‑receptor antagonists.

In the context of accidental ingestion of lafutidine tablets by a breastfeeding infant, management should follow standard pediatric toxicology principles, with particular attention to airway protection, hemodynamic stability, and monitoring for CNS or gastrointestinal symptoms.
Poison center consultation is recommended in moderate or severe exposures, as published pediatric overdose data for lafutidine are lacking.

Summary for clinical use in lactation

Lafutidine, as an H2‑receptor antagonist with multimodal gastroprotective activity, shows low acute toxicity and good tolerability in adults at therapeutic doses.
Although direct milk‑excretion data are unavailable, extrapolation from its pharmacokinetic profile and extensive class experience suggests low infant exposure and low risk when used in standard doses during breastfeeding, supporting its Lactologia category II placement with the usual precautions and preference for better‑studied alternatives when possible.